Trade-Ideas: Tekmira Pharmaceuticals (TKMR) Is Today's Post-Market Leader Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Tekmira Pharmaceuticals ( TKMR) as a post-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Tekmira Pharmaceuticals as such a stock due to the following factors:

  • TKMR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $101.0 million.
  • TKMR is up 3.4% today from today's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in TKMR with the Ticky from Trade-Ideas. See the FREE profile for TKMR NOW at Trade-Ideas

More details on TKMR:

Tekmira Pharmaceuticals Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics; and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. Currently there are 6 analysts that rate Tekmira Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Tekmira Pharmaceuticals has been 2.5 million shares per day over the past 30 days. Tekmira has a market cap of $398.3 million and is part of the health care sector and drugs industry. Shares are up 140% year-to-date as of the close of trading on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates Tekmira Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.

Highlights from the ratings report include:
  • TEKMIRA PHARMACEUTICALS CORP's earnings per share declined by 27.3% in the most recent quarter compared to the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. During the past fiscal year, TEKMIRA PHARMACEUTICALS CORP swung to a loss, reporting -$0.96 versus $1.87 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 96.5% when compared to the same quarter one year ago, falling from -$3.11 million to -$6.10 million.
  • The revenue fell significantly faster than the industry average of 43.4%. Since the same quarter one year prior, revenues fell by 38.5%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.
  • Compared to its closing price of one year ago, TKMR's share price has jumped by 252.11%, exceeding the performance of the broader market during that same time frame. Regarding the future course of this stock, we feel that the risks involved in investing in TKMR do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

FANG Stocks Get Swept Up in Broader Market Selloff

FANG Stocks Get Swept Up in Broader Market Selloff

Snap Shares Plunge After Cowen Cuts Price Target

Snap Shares Plunge After Cowen Cuts Price Target

Dow Tumbles as Trump Ratchets Up China Trade Fight

Dow Tumbles as Trump Ratchets Up China Trade Fight

Jim Cramer: Aramark Is a Great Company but It's Levered to Baseball

Jim Cramer: Aramark Is a Great Company but It's Levered to Baseball

Preferred Stock & Common Stock: What's the Difference?

Preferred Stock & Common Stock: What's the Difference?